| The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota J Boursier, O Mueller, M Barret, M Machado, L Fizanne, F Araujo‐Perez, ... Hepatology 63 (3), 764-775, 2016 | 996 | 2016 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 949 | 2016 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 949 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 734 | 2019 |
| Determination of reliability criteria for liver stiffness evaluation by transient elastography J Boursier, JP Zarski, V de Ledinghen, MC Rousselet, N Sturm, B Lebail, ... Hepatology 57 (3), 1182-1191, 2013 | 527 | 2013 |
| Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy C Cassinotto, J Boursier, V de Lédinghen, J Lebigot, B Lapuyade, ... Hepatology 63 (6), 1817-1827, 2016 | 466 | 2016 |
| A placebo-controlled trial of bezafibrate in primary biliary cholangitis C Corpechot, O Chazouillères, A Rousseau, A Le Gruyer, F Habersetzer, ... New England Journal of Medicine 378 (23), 2171-2181, 2018 | 394 | 2018 |
| Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease J Boursier, J Vergniol, A Guillet, JB Hiriart, A Lannes, B Le Bail, ... Journal of hepatology 65 (3), 570-578, 2016 | 339 | 2016 |
| Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease MV Machado, GA Michelotti, G Xie, TP de Almeida, J Boursier, B Bohnic, ... PloS one 10 (5), e0127991, 2015 | 331 | 2015 |
| Comparison of blood tests for liver fibrosis specific or not to NAFLD P Calès, F Lainé, J Boursier, Y Deugnier, V Moal, F Oberti, G Hunault, ... Journal of hepatology 50 (1), 165-173, 2009 | 314 | 2009 |
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation … PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ... The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020 | 309 | 2020 |
| EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update CPG Panel, A Berzigotti, E Tsochatzis, J Boursier, L Castera, N Cazzagon, ... Journal of hepatology 75 (3), 659-689, 2021 | 278 | 2021 |
| Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial P Mathurin, A Louvet, A Duhamel, P Nahon, N Carbonell, J Boursier, ... Jama 310 (10), 1033-1041, 2013 | 245 | 2013 |
| Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis J Boursier, G Isselin, I Fouchard-Hubert, F Oberti, N Dib, J Lebigot, ... European journal of gastroenterology & hepatology 22 (9), 1074-1084, 2010 | 181 | 2010 |
| Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis A Louvet, J Labreuche, F Artru, J Boursier, DJ Kim, J O’Grady, E Trépo, ... Gastroenterology 149 (2), 398-406. e8, 2015 | 164 | 2015 |
| Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C J Vergniol, J Boursier, C Coutzac, S Bertrais, J Foucher, C Angel, ... Hepatology 60 (1), 65-76, 2014 | 160 | 2014 |
| Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C P Calès, V De Ledinghen, P Halfon, Y Bacq, V Leroy, J Boursier, ... Liver International 28 (10), 1352-1362, 2008 | 147 | 2008 |
| Reproducibility of liver stiffness measurement by ultrasonographic elastometry J Boursier, A Konaté, G Gorea, S Reaud, E Quemener, F Oberti, ... Clinical Gastroenterology and Hepatology 6 (11), 1263-1269, 2008 | 144 | 2008 |
| The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis J Boursier, J Vergniol, A Sawadogo, T Dakka, S Michalak, Y Gallois, ... Liver International 29 (10), 1507-1515, 2009 | 142 | 2009 |
| Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive J Boursier, V de Ledinghen, JP Zarski, I Fouchard‐Hubert, Y Gallois, ... Hepatology 55 (1), 58-67, 2012 | 140 | 2012 |
